UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

In vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [11C]ABP688 and [18F]FPEB

Journal of cerebral blood flow and metabolism, 2017-08, Vol.37 (8), p.2716-2727

2017

Volltextzugriff (PDF)

Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging Study

Biological psychiatry : cognitive neuroscience and neuroimaging, 2017-07, Vol.2 (5), p.449-456

2017

Volltextzugriff (PDF)

Development of mavoglurant and its potential for the treatment of fragile X syndrome

Expert opinion on investigational drugs, 2014-01, Vol.23 (1), p.125-134

2014

Volltextzugriff (PDF)

Metabotropic Glutamate Receptors for Parkinson's Disease Therapy

Parkinson's disease, 2013-01, Vol.2013 (2013), p.1-11

2013

Volltextzugriff (PDF)

Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents

The Journal of pharmacology and experimental therapeutics, 2000-12, Vol.295 (3), p.1267

2000

Volltextzugriff (PDF)

The Non-competitive Antagonists 2-Methyl-6-(phenylethynyl)pyridine and 7-Hydroxyiminocyclopropan[b]chromen-1a-carboxylic Acid Ethyl Ester Interact with Overlapping Binding Pockets in the Transmembrane Region of Group I Metabotropic Glutamate Receptors

The Journal of biological chemistry, 2000-10, Vol.275 (43), p.33750-33758

2000

Volltextzugriff (PDF)

CPCCOEt, a Noncompetitive Metabotropic Glutamate Receptor 1 Antagonist, Inhibits Receptor Signaling Without Affecting Glutamate Binding

Molecular pharmacology, 1999-03, Vol.55 (3), p.453

1999

Volltextzugriff (PDF)

Design and Synthesis of Selective and Potent Orally Active S1P5 Agonists

ChemMedChem, 2010-10, Vol.5 (10), p.1693-1696

2010

Volltextzugriff (PDF)

SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5

The Journal of pharmacology and experimental therapeutics, 1999-07, Vol.290 (1), p.170

1999

Volltextzugriff (PDF)

Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome

Nature reviews. Drug discovery, 2018-04, Vol.17 (4), p.280-299

2018

Volltextzugriff (PDF)

Radiation dosimetry and biodistribution of 11C-ABP688 measured in healthy volunteers

European journal of nuclear medicine and molecular imaging, 2008-04, Vol.35 (4), p.766-770

2008

Volltextzugriff (PDF)

THE CMS MUON DETECTOR: FROM THE FIRST THOUGHTS TO THE FINAL DESIGN

International journal of modern physics. A, Particles and fields, gravitation, cosmology, 2010-06, Vol.25 (16), p.3121-3154

GASPARINI, FABRIZIO

2010

Volltextzugriff (PDF)

Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056

Science translational medicine, 2011-01, Vol.3 (64), p.64ra1

2011

Volltextzugriff (PDF)

AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials

Movement disorders, 2011-06, Vol.26 (7), p.1243-1250

2011

Volltextzugriff (PDF)

Translating molecular advances in fragile X syndrome into therapy: a review

The journal of clinical psychiatry, 2014-04, Vol.75 (4), p.e294-e307

2014

Volltextzugriff (PDF)

A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease

Movement disorders, 2015-03, Vol.30 (3), p.427-431

2015

Volltextzugriff (PDF)

Pharmacological modulation of mGluR7 with AMN082 and MMPIP exerts specific influences on alcohol consumption and preference in rats

Addiction biology, 2012-03, Vol.17 (2), p.235-247

2012

Volltextzugriff (PDF)

The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice

Psychopharmacologia, 2003-05, Vol.167 (3), p.257-264

2003

Volltextzugriff (PDF)

Group II metabotropic and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats

The Journal of pharmacology and experimental therapeutics, 2003-09, Vol.306 (3), p.1068-1076

2003

Volltextzugriff (PDF)

Mavoglurant Augmentation in OCD Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Proof-of-Concept, Randomized, Placebo-Controlled, Phase 2 Study

Advances in therapy, 2017-02, Vol.34 (2), p.524-541

2017

Volltextzugriff (PDF)

Metabotropic glutamate 5 receptor blockade may attenuate cocaine self-administration by decreasing brain reward function in rats

Psychopharmacology, 2005-04, Vol.179 (1), p.247-254

2005

Volltextzugriff (PDF)

Dose-dependent, saturable occupancy of the metabotropic glutamate subtype 5 receptor by fenobam as measured with [11C]ABP688 PET imaging

Synapse (New York, N.Y.), 2014-12, Vol.68 (12), p.565-573

2014

Volltextzugriff (PDF)

Effect of l-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys

Journal of neurochemistry, 2010-05, Vol.113 (3), p.715-724

2010

Volltextzugriff (PDF)

Nicotine potentiation of brain stimulation reward reversed by DHβE and SCH 23390, but not by eticlopride, LY 314582 or MPEP in rats

Psychopharmacologia, 2002-02, Vol.160 (1), p.56-66

2002

Volltextzugriff (PDF)

Decrease of mGluR5 receptor density goes parallel with changes in enkephalin and substance P immunoreactivity in Huntington’s disease: a preliminary investigation in the postmortem human brain

Brain Structure and Function, 2015-09, Vol.220 (5), p.3043-3051

2015

Volltextzugriff (PDF)

1 – 25 von 92

Suche als RSS-Feed

Aktive Filter

KollektionElsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)

KollektionIngentaConnect

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(78)
Mit Volltextzugriff
(68)

Publikationsform

Sprache

Englisch
(91)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(63)
Life Sciences & Biomedicine
(58)
Humans
(43)
Male
(33)
Animals
(24)
Female
(24)
Receptors, Metabotropic Glutamate - Antagonists & Inhibitors
(18)
Neurosciences & Neurology
(17)
Middle Aged
(16)
Pharmacology & Pharmacy
(14)
Aged
(13)
Biological And Medical Sciences
(13)
Medical Sciences
(13)
Receptor, Metabotropic Glutamate 5
(13)
Adult
(12)
Neurosciences
(12)
Oncology
(12)
Rats
(12)
Excitatory Amino Acid Antagonists - Pharmacology
(10)
Pyridines - Pharmacology
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

In vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [11C]ABP688 and [18F]FPEB

Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging Study

Development of mavoglurant and its potential for the treatment of fragile X syndrome

Metabotropic Glutamate Receptors for Parkinson's Disease Therapy

Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents

The Non-competitive Antagonists 2-Methyl-6-(phenylethynyl)pyridine and 7-Hydroxyiminocyclopropan[b]chromen-1a-carboxylic Acid Ethyl Ester Interact with Overlapping Binding Pockets in the Transmembrane Region of Group I Metabotropic Glutamate Receptors

CPCCOEt, a Noncompetitive Metabotropic Glutamate Receptor 1 Antagonist, Inhibits Receptor Signaling Without Affecting Glutamate Binding

Design and Synthesis of Selective and Potent Orally Active S1P5 Agonists

SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5

Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome

Radiation dosimetry and biodistribution of 11C-ABP688 measured in healthy volunteers

THE CMS MUON DETECTOR: FROM THE FIRST THOUGHTS TO THE FINAL DESIGN

Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056

AFQ056 treatment of levodopa-induced dyskinesias: Results of 2 randomized controlled trials

Translating molecular advances in fragile X syndrome into therapy: a review

A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease

Pharmacological modulation of mGluR7 with AMN082 and MMPIP exerts specific influences on alcohol consumption and preference in rats

The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice

Group II metabotropic and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats

Mavoglurant Augmentation in OCD Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Proof-of-Concept, Randomized, Placebo-Controlled, Phase 2 Study

Metabotropic glutamate 5 receptor blockade may attenuate cocaine self-administration by decreasing brain reward function in rats

Dose-dependent, saturable occupancy of the metabotropic glutamate subtype 5 receptor by fenobam as measured with [11C]ABP688 PET imaging

Effect of l-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys

Nicotine potentiation of brain stimulation reward reversed by DHβE and SCH 23390, but not by eticlopride, LY 314582 or MPEP in rats

Decrease of mGluR5 receptor density goes parallel with changes in enkephalin and substance P immunoreactivity in Huntington’s disease: a preliminary investigation in the postmortem human brain

Aktive Filter

Suchergebnisse filtern